MYCO-005 explained

Class:Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
Synonyms:MYCO005

MYCO-005 is a serotonin 5-HT2A receptor agonist and psychedelic hallucinogen which is under development for the treatment of depressive disorders and anxiety disorders.[1] [2] [3] [4] [5]

It is a tryptamine derivative and an analogue of psilocin. However, whereas psilocin and other tryptamines show high affinity for and potent activation of not only the serotonin 5-HT2A receptor but also the serotonin 5-HT2B receptor, MYCO-005 does not bind to this receptor. Activation of the serotonin 5-HT2B receptor is known to induce the development of cardiac valvulopathy and has been a concern with regard to chronic microdosing of psychedelics.[6] [7] Since MYCO-005 does not activate the serotonin 5-HT2B receptor, it is anticipated to be heart-safe and to be safer for use in the contexts of both macro- and microdosing than other psychedelics.

As of February 2024, MYCO-005 is in the research stage of development for depressive disorders and anxiety disorders. It is being developed by Mydecine. The exact chemical structure of MYCO-005 does not yet seem to have been disclosed. However, the compound was patented in 2023 and the specified patent specifically describes aza-substituted psilocin analogues.[8]

Notes and References

  1. Web site: Research programme: second generation psilocin analogs . AdisInsight . 13 February 2024 . 1 November 2024 . A family of psilocin analogs (MYCO 005) with heart-safe microdose enabling properties is being developed by Mydecine Innovations Group for the treatment of [...].
  2. Web site: Delving into the Latest Updates on MYCO-005 with Synapse . Synapse . 1 November 2024 . 1 November 2024.
  3. Web site: MYCO-005 Drug Profile . Ozmosi . 26 October 2023 . 1 November 2024.
  4. Web site: Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules . BioSpace . 16 February 2022 . 1 November 2024.
  5. Web site: Mydecine Innovations Group . Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound . Yahoo Finance . 18 December 2023 . 1 November 2024.
  6. Tagen M, Mantuani D, van Heerden L, Holstein A, Klumpers LE, Knowles R . The risk of chronic psychedelic and MDMA microdosing for valvular heart disease . J Psychopharmacol . 37 . 9 . 876–890 . September 2023 . 37572027 . 10.1177/02698811231190865 .
  7. Rouaud A, Calder AE, Hasler G . Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins . J Psychopharmacol . 38 . 3 . 217–224 . March 2024 . 38214279 . 10944580 . 10.1177/02698811231225609 .
  8. Web site: Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same . Google Patents . 1 May 2023 . 1 November 2024.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "MYCO-005".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.